Abstract
Anemia is a frequent complication of multiple myeloma, becoming chronic in patients who are resistant to chemotherapy. This randomized, parallel, controlled multicenter study (71 patients receiving concomitant chemotherapy) evaluated the efficacy and safety of epoetin alfa in improving anemia and eliminating the need for transfusions in multiple myeloma patients refractory to conventional first- or second-line chemotherapy. Forty patients were treated with subcutaneous epoetin alfa (150 IU/kg per dose, increasing to 300 IU/kg per dose, every 3 weeks) for 6 months, and 31 entered a control group. The epoetin alfa group had a significantly (P≤0.001) greater percentage of patients (75% vs. 21%) with increases in hemoglobin levels and/or reduced transfusion requirements. In 44 non pre-transfused patients (20 controls, 24 in the epoetin alfa group), the mean increase in hemoglobin was significantly (P≤0.0001) greater in the epoetin alfa group (+2.1 vs. −0.2 g/dl). Increases in hematocrit and red blood cells were also significantly (P≤0.0001) greater in epoetin alfa-treated patients, with corresponding reductions in transfusion requirement. In the 27 pre-transfused patients (11 controls, 16 in the epoetin alfa group), there was a trend towards reduced transfusional need in epoetin alfa-treated patients. Thus, in patients with multiple myeloma refractory to chemotherapy epoetin alfa is a well-tolerated treatment which improves anemia in non pre-transfused patients and appears to reduce transfusion need in those previously transfused.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Skillings JR, Sridhar FG, Wong C, Paddock L. The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. Am J Clin Oncol 1993; 16: 22.
Kreider E. A retrospective study to estimate the need for recombinant human erythropoietin in the treatment of anemia in cancer patients (abstract). Ann Oncol 1994; 5 Suppl 8: 477.
Kuzur ME, Greco FA. Cisplatin-induced anemia. N Engl J Med 1980; 303: 110.
Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener HC, Cruichshank DJ, Atkinson RJ, Soukop M, Rankin EM. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992; 340: 329.
Gale RP. Anti-neoplastic chemotherapy myelosuppression: mechanisms and new approaches. Exp Hematol 1985; 13 Suppl 16: 3.
Matsumoto T, Endoh K, Kamisango K, Akamatsu KI, Koizumi K, Higuchi M, Imai N, Mitsui H, Kawaguchi T. Effect of recombinant human erythropoietin on anticancer drug-induced anaemia. Br J Haematol 1990; 75: 463.
Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with anemia of cancer. N Engl J Med 1990; 322: 1689.
Schapira L, Antin JH, Ransil BJ, Antman KH, Eder JP, McCarigle C, Goldberg MA. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 1990; 76: 2354.
Rothman SA, Paul P, Weick JK, McIntyre, Fantelli F. Effect of cis-diaminedichloroplatinum on erythropoietin production and hematopoietic progenitor cells. Int J Cell Cloning 1985; 3: 415.
Kyle RA, Bayrd ED. The monoclonal gammopathies: multiple myeloma and related plasma-cell disorders. Springfield, Illinois; Thomas, 1976.
Barlogie B, Epstein J, Selvanayagam P, Alexanian R. Plasma cell myeloma — new biological insights and advances in therapy. Blood 1989; 73: 865.
Platanias LC, Miller CB, Mick R, Hart RD, Ozer H, McEvilly J-M, Jones RJ, Ratain MJ. Treatment of chemotherapy-induced anaemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 1991; 9: 2021.
Cazzola M, Ponchio L, Beguin Y, Rosti V, Bergamaschi G, Liberato NL, Fregoni V, Nalli G, Barosi G, Ascari E. Subcutaneous erythropoietin for treatment of refractory anemia in hematological disorders. Results of a phase I/II clinical trial. Blood 1992; 79: 29.
Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993; 29A Suppl 2: S2.
Ludwig H, Fritz E, Leitgeb C, Krainer M, Kuhrer I, Sagaster P, Umek H. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 1993; 4: 161.
Case DC, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones SE, Keller AM, Kugler JW, Nichols CR. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993; 85: 801.
Silvestris F, Romito A, Fanelli P, Vacca A, Dammacco F. Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol 1995; 70: 313.
Ludwig H, Fritz E, Kotzmann H, Höcker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990; 322: 1693.
Taylor J, Mactier RA, Stewart WK, Henderson IS. Effect of erythropoietin on anaemia in patients with myeloma receiving haemodialysis. BMJ 1990; 303: 476.
Garton JP, Gerts MA, Witzig TE, Greipp PR, Lust JA, Schroeder G, Kyle RA. Epoetin alfa for the treatment of anemia of multiple myeloma: a prospective, randomized, placebo-controlled double-blind trial. Arch Intern Med 1995; 155: 2069.
Barlogie B, Beck T. Recombinant human erythropoietin and the anaemia of multiple myeloma. Stem Cells (Dayt) 1993; 11: 88.
DeFronzo RA, Cooke CR, Wright JR, Humphrey RL. Renal function in patients with multiple myeloma. Medicine (Baltimore) 1978; 57: 151.
Bukowski R, Glapsy J, Steinberg D, Taylor CW, Vadhan-Rai S, Danna RP, Sarokhan B, Lonczak L, McNeill M. Phase IV evaluation of clinical outcomes of Procrit (epoetin alfa) in anemic cancer patients receiving chemotherapy. Blood 1994; 84 Suppl 1: 129a.
Rose E, Rai K, Revicki D, Brown R, Reblando J and the EPO in Anemia of CLL Study Group. Clinical and health status assessment in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 1994; 84 Suppl 1: 526a.
Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A, Jäger G, LeMevel A, Najman A, Silingardi V, Spirano M, Van Hoof A, Ehmer B. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 1995; 86: 4446.
Österborg, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jäger G, Najman A, Peest D. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma — a randomised multicenter study. Blood 1996; 87: 2675.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dammacco, F., Silvestris, F., Castoldi, G.L. et al. The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 28, 127–134 (1998). https://doi.org/10.1007/s005990050032
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s005990050032